Abstract: Cancer metastasis is facilitated by cell-cell interactions between cancer cells and endothelial cells in distant tissues. In addition, cancer cell interactions with platelets and leukocytes contribute to cancer cell adhesion, extravasation, and the establishment of metastatic lesions. Selectins are carbohydratebinding molecules that bind to sialylated, fucosylated glycan structures, and are found on endothelial cells, platelets and leukocytes. There are three members of the selectin family: P-selectin expressed on activated platelets and endothelial cells, L-selectin present on leukocytes and E-selectin expressed on activated endothelial cells. Besides the accepted roles of selectins in physiological processes, such as inflammation, immune response and hemostasis, there is accumulating evidence for the potential of selectins to contribute to a number of pathophysiological processes, including cancer metastasis. Cancer cell interactions with selectins are possible due to a frequent presence of carbohydrate determinantsselectin ligands on the cell surface of tumor cells from various type of cancer. The degree of selectin ligand expression by cancer cells is well correlated with metastasis and poor prognosis for cancer patients. Initial adhesion events of cancer cells facilitated by selectins result in activation of integrins, release of chemokines and are possibly associated with the formation of permissive metastatic microenvironment. While E-selectin has been evaluated as one of the initiating adhesion events during metastasis, it is becoming apparent that P-selectin and L-selectin-mediated interactions significantly contribute to this process as well. In this review we discuss the current evidence for selectins as potential facilitators of metastasis. is becoming apparent that P-selectin and L-selectin mediated interactions significantly contribute to this process as well. In this review we discuss the current evidence for selectins as potential facilitators of metastasis.
Introduction
Hematogenous metastasis of cancer consists of several steps enabling cancer cells to intravasate, to survive in the blood circulation and to adhere to the vessels, eventually extravasating and establishing new metastatic lesions. Interactions of intravascular cancer cells with blood constituents (platelets, leukocytes) can modulate their capacity to adhere to endothelium in distant organs thereby facilitating metastasis. This process of cancer cell adhesion and seeding to specific vascular beds appears to be a rate limiting step in cancer metastasis. It is well accepted that malignant transformation is associated with abnormal glycosylation resulting in presentation of altered carbohydrate structures. Enhanced expression of sialyl Lewis x and sialyl Lewis a structures is frequently associated with cancer progression and poor prognosis [1] . At the same time, these carbohydrates are recognized selectin ligands. Selectins are vascular cell adhesion molecules involved in interactions of leukocytes, platelets and endothelium.
Due to the temporal and spatial presence of selectins during hematogeneous dissemination and early organ colonization, interactions with carbohydrate ligands on cancer cells can be expected. Studies from several laboratories suggest that metastatic cancer cells exploit similar mechanisms as used by leukocytes for adhesion and extravasation through endothelium that may contribute to metastasis [2, 3] . Recent evidence also indicates that selectin-mediated interactions may contribute to formation of a permissive microenvironment for metastasis [4] .
Selectins -vascular cell adhesion molecules
Selectins were identified to be the key adhesion molecules that mediate leukocyte trafficking and hemostasis, soon after their cloning and characterization [5] [6] [7] .
Subsequently, selectins were implicated in many human diseases including cancer [3, [7] [8] [9] [10] . Selectins are type-I transmembrane glycoproteins consisting of an extracellular Ctype lectin domain, an EGF domain, two to nine consensus repeats, a transmembrane domain and a cytoplasmic tail [5] . L-selectin is constitutively expressed on all myeloid cells, on naïve T-cells and some activated memory T-cells [5, 11] . Activation of leukocytes leads to a rapid loss of L-selectin from their cell surfaces due to a proteolytic cleavage [7] . P-selectin is constitutively expressed in endothelial cells of the lung and the choroid plexus, megakaryocytes, thrombocytes and is stored within Weibel-Pallade bodies of endothelial cells or alpha-granules of platelets, respectively [5, 6] . P-selectin is rapidly presented on the surface of activated endothelial cells or platelets by means of exocytosis of storage granules and their fusion with the cell membrane [12] [13] [14] . Eselectin is expressed exclusively by endothelial cells, mainly in response to local activation [5] . Constitutive expression of E-selectin has been detected in the skin and parts of bone marrow microvasculature [15] . In most vessels de novo synthesis and expression of E-selectin can be induced within two to six hours in response to inflammatory stimuli (e.g. TNF-α and IL-1β) or disturbed blood flow [5, 16] . Expression of P-and E-selectin is tightly regulated during homeostasis, thereby ensuring spatial and temporal adhesion/recruitment of leukocytes. However, E-selectin may remain upregulated in the endothelium in areas of chronic inflammation [17, 18] .
Selectin ligands
Selectin-based adhesion is mediated by heterotypic interactions of their C-type lectin domain with glycan-bearing ligands. Functional selectin ligands require post-translational modification of scaffold proteins by glycosyltransferases and sulfotransferases [5, [19] [20] [21] . The minimal recognition motif for all selectins is the sialyl- [5, 20] . P-selectin glycoprotein ligand-1 (PSGL-1) is the best characterized ligand, which is concentrated on the tips of microvilli on leukocyte cell surfaces. All three selectins bind to PSGL-1, while potent binding of P-and Lselectin to PSGL-1 is facilitated by additional sulfation of the amino-terminal part of the protein [5, 6] . Although leukocytes express a number of different selectin ligands, e.g.
CD44 [23] , or E-selectin ligand-1 (ESL-1) [24] , PSGL-1 is the main physiological ligand for P-selectin [5, 6] . L-selectin mediates the trafficking of leukocytes, in particular lymphocytes through binding to peripheral node addressins (PNAds) that are endothelial glycoproteins [21] . E-selectin binds to a number of ligands, including PSGL-1, ESL-1, CD44, CD43, β2-integrins, and L-selectin [5, [25] [26] [27] [28] [29] . Mucins are major carriers of altered glycosylation that occur during progression of epithelial cancers -carcinomas. Mucins are high-molecular-weight molecules containing a protein core substituted with a large number of O-linked glycan structures [9, 30] . Major alterations are an enhanced expression of sLe x/a , or Tn and sialyl-Tn antigen structures on mucins [31] . Carcinoma mucins expressing sLe x/a structures are major selectin ligands on cancer cells. In addition to mucins, several other selectin ligands on cancer cells have been described including CD24, CD44, death-receptor 3, ESL-1 and PSGL-1 [32] [33] [34] [35] . However, the in vivo relevance of these ligands remains to be determined [24] . Finally, P-and L-selectin,
but not E-selectin can bind to sulfated glycans including heparin, heparin sulfate, fucoidan and sulfated glycolipids in a calcium-independent manner [20, 36] . The large variety of different carbohydrate structures recognized by selectins indicates that the lectin domain of selectins recognize a certain carbohydrate "patch" that can be generated in different ways [20] .
Roles of selectins health and disease
The characterization of selectin and selectin ligand deficient mice has provided information about the physiological functions of selectins in inflammation, immune response, wound repair and hemostasis [37] [38] [39] [40] [41] . These findings have been further confirmed in mice deficient in selectin ligands, e.g. FucT-VII, Core 2 glucosaminyltransferase, or PSGL-1 [42] [43] [44] [45] . Extravasation of leukocytes comprises sequential steps including tethering of leukocytes on endothelial cells, fast and slow rolling, firm adhesion and trans-or para-endothelial migration [46, 47] . Selectins mediate the initial tethering and are critically involved in the transition from fast to slow rolling before leukocytes firmly adhere to endothelial cells [5, 6, 47] . Transition from fast to slow rolling requires activation of integrins that is in part supported by selectin or PSGL-1 outside-in signaling [48, 49] . Given the central role in leukocyte extravasation and trafficking, selectins are involved in innate and adaptive immune responses and this topic is extensively covered elsewhere [5, 21, 47] . Importantly, cell homing studies in mice showed that adhesion of leukocytes differs between organs and types of inflammation [7, 50] .
P-selectin on platelets is involved in thrombus formation during hemostasis [51, 52] . The procoagulant activity of P-selectin is mainly explained by its role in the formation of leukocyte derived microparticles containing tissue factor, the key inducer of the extrinsic coagulation cascade [52, 53] . Moreover, PSGL-1 on platelets could enhance interactions between them and mediate binding of platelets to P-and E-selectin on activated endothelial cells, thus influencing hemostasis [54] .
Acute systemic inflammatory responses to infectious or toxic stimulants and trauma are uncontrolled inflammatory, life threatening events that can lead to SIRS (systemic inflammatory response syndrome), sepsis and eventually to multi-organ failure [55] .
Selectins are involved in acute organ damage during sepsis by mediating the recruitment of myeloid cells [56] . In different disease models, P-or E-selectin deficient mice are protected from acute inflammation and tissue damage [57, 58] . L-selectin deficiency also decreases leukocyte recruitment to sites of acute inflammation [59] .
Inhibition of E-or P-selectin by antibodies or heparin showed significantly reduced disseminated intravascular coagulation and mortality in an experimental septic shock model [60] .
Chronic inflammation plays a key role in atherosclerosis, the main cause of morbidity and mortality in developed nations [61] . Recruitment of inflammatory cells during progression of the atherosclerotic lesion is partially selectin dependent [61] . The absence of P-selectin reduces atherosclerotic lesions due to reduced monocyte recruitment [62] . Monocyte recruitment during atherogenesis is facilitated by P-selectin on activated platelets adherent on the endothelium [63] . P-selectin mediated rolling of platelets on activated endothelial cells further supports progression of atherosclerotic lesions [64] . Atherosclerosis is partly decreased by the absence of E-selectin [65] .
Finally, L-selectin was recently implicated in atherosclerosis by enhancing lymphocyte recruitment [66] .
Selectin interactions beyond cell adhesion
Selectin-mediated interactions facilitate not only cell adhesion, but may also participate in signal transduction, thereby affecting cell migration and activation of other adhesion molecules including integrins [47] [48] [49] 67] . Selectin engagement can trigger signals in both the selectin-expressing and the ligand-expressing cells [68, 69] . While the signaling pathways for selectins are just being revealed, leukocyte extravasation represents the best described selectin-initiated signaling pathway [47] . Binding of L-selectin can activate leukocytes and affect the cytoskeleton trough interactions between the cytoplasmic tail of L-selectin with α-actinin, ezrin/radixin/moesin (ERM) family proteins, calmodulin, increase of intracellular calcium and induction of the p38 mitogen-activated kinase pathway [49, [70] [71] [72] [73] [74] . L-selectin mediated activation of neutrophils can lead to the production of reactive oxygen species, TNF-α, interleukin-8 and integrins, including CD11b [49, 75] . Monocytes can be activated by the engagement of PSGL-1 on their surfaces by P-selectin [76] . P-selectin binding to PSGL-1 induces signaling that activates integrins through the Src kinase family, Nef-associated factor 1 and phosphoinositide-3-OH-kinases [48, 77, 78] . The cytoplasmic tail of PSGL-1 also interacts via ERM proteins with the cytoskeleton and the spleen tyrosine kinase (SYK)
that may transmit signals [79, 80] . There is also evidence that the engagement of Pselectin transmits signals to endothelial cells and platelets, while the mechanism remains unclear [49] . E-selectin binding to PSGL-1 activates β2 integrins through the SYK and Src kinase pathway that is required for initiation of neutrophil slow rolling [81] .
E-selectin itself can transduce signals into endothelial cells through p38 and p42/p44 MAPK pathway [69] . Finally, selectin binding to cell-surface-bound mucins may also transmit signals into cancer cells during cancer progression, e.g. by enhancing growth factor receptor signaling [30, 82] .
Selectins and cancer progression
How cancer cells metastasize is still not completely understood. affecting the progression of the disease [10, 86, 87] .
E-selectin during cancer progression
E-selectin is a major adhesion receptor on endothelial cells for leukocytes and has been repeatedly shown to support metastasis in vivo [88, 89] . E-selectin has been investigated as a mediator of the process by which cancer cells adhere/arrest in the microvasculature during metastasis [3, 90, 91] . The presence of E-selectin ligands on cancer cells correlates with enhanced adhesion to activated endothelium [92] [93] [94] [95] . Eselectin ligands on cancer cells have been found to be mostly mucins [96] , yet several unique E-selectin ligands have been recently identified on cancer cells, including dead receptor-3 and a specific CD44 glycoform [33, 34] . E-selectin binding of death receptor 3 or other ligands on cancer cells has been shown to increase survival during metastasis [34, 97] . Recent work provides evidence that E-selectin binding to cancer cells may alter the gene expression profile of cancer cells [97] . Furthermore, E-selectin has been shown to regulate endothelial transmigration through activation of p38 and ERK AP kinases [98, 99] . Since distinct E-selectin ligands on neutrophils have been shown to induce different reactions [24] , it can be expected that the nature of E-selectin ligands presented on cancer cells may induce specific processes both in endothelial cells as well as in cancer cells.
E-selectin is expressed on activated endothelial cells and has been shown to be upregulated during metastatic colonization of the liver [88, 89] . Downregulation of Eselectin expression or inhibition of E-selectin function resulted in attenuation of experimental liver metastasis. In a transgenic mouse model over-expressing E-selectin in the liver, metastases were redirected to this organ, thus confirming the role of Eselectin in this process [100] . In an experimental metastasis model where mice were injected with IL-1, co-injection of cancer cells with soluble E-selectin probe led to a reduction of metastasis in the lungs [93] . However, induced E-selectin expression by a high cytokine dose does not reflect the natural process of metastatic lung colonization.
We recently demonstrated that E-selectin is disposable in a model of experimental lung metastasis [101] . These findings probably reflect organ specific differences in the colonization process and different requirements for selectin-mediated interactions depending on the primary tumor and the metastatic organ. Nevertheless, in vivo evidence for cancer cell rolling on activated endothelium mediated through E-selectin that leads to metastatic colonization requires further investigation.
P-selectin during cancer progression
The close "relationship" of circulating cancer cells with platelets is one of the factors contributing to cancer progression [14, [102] [103] [104] . Substantial evidence indicates that platelets interact with circulating cancer cells, thereby creating tumor microemboli that may facilitate arrest in distant organs and subsequently promote interactions with endothelium [102, 103] . Evidence that platelets support metastasis initially came from models of experimentally induced thrombocytopenia [105, 106] . Likewise, plateletdeficient mice lacking Nf-E2 showed reduced metastasis [107] . The underlying mechanism for the initiation of platelet-cancer cell thrombi formation remains to be defined. However, experimental evidence strongly indicates that platelet P-selectin contributes to the thrombi formation and aids colonization of cancer cells in the lungs [84, 108] . Platelet aggregates on cancer cells lodged in the vasculature was virtually absent in P-selectin deficient mice and was associated with a limited initial seeding of cancer cells to the lungs [108] . Platelets were shown to bind to cancer cells through carcinoma cell surface mucins in a P-selectin dependent manner. Removal of cell surface mucins from cancer cells prior to intravenous injection resulted in attenuation of metastasis [108] . Bone marrow transplantation experiments in P-selectin deficient mice have shown that endothelial P-selectin also contributes to metastasis [109] .
Furthermore, inhibition of P-selectin-mediated interactions of platelets with cancer cell ligands by heparin treatment attenuates cancer metastasis in mice [108, 109] .
Patients suffering from advanced cancer are at high risk for thromboembolic events, a finding initially described by Trousseau [87] . The particular association between thrombotic diathesis and mucinous carcinomas led to hypothesis that mucins, carrying selectin ligands, trigger this syndrome. Intravenous injection of purified carcinoma mucins led to a rapid generation of platelet-rich microthrombi [87] . Interestingly, in Pselectin but also L-selectin deficient mice the microthrombi generation was markedly diminished, indicating the involvement of platelet P-selectin and leukocytes in thrombotic events accompanying cancer progression.
L-selectin during cancer progression
Initial studies focused on the potential role of L-selectin on tumor cells by homing to Lselectin ligand expressing tissues [110, 111] . Transgenic ectopic expression of Lselectin in a spontaneous mouse carcinoma model facilitated lymph node metastasis [110] . However, naturally occurring L-selectin on a B-cell lymphoma cell line was not associated with enhanced lymph node metastasis [111] .
Inflammation is a key component of the tumor microenvironment and leukocytes have been shown to promote both primary tumor growth as well as metastatic dissemination [112, 113] . Leukocyte responses to cancer are not unique, and have many parallels with the inflammatory response to infection and during wound healing [112, 114] .
Contribution of leukocytes to metastasis largely depends on spatial and temporal stimulation that is defined by the microenvironment and cancer cells [112, 114, 115] . Lselectin-mediated leukocyte recruitment to locally activated endothelial cells is one possible means that may be exploited by cancer cells. The contribution of L-selectin to metastasis was analyzed in L-selectin deficient mice [83, 85] . The absence of L-selectin led to attenuation of metastasis. This finding actively implicates leukocytes to the process of metastasis, since L-selectin expression is restricted to leukocytes [83] . Lselectin mediated recruitment of leukocytes to tumor emboli was found to occur subsequent to P-selectin-mediated platelet-cancer cell complex formation [85, 101] . 
Selectins promote metastasis by shaping the metastatic niche
There is sufficient experimental evidence that selectins mainly promote metastasis by facilitating heterotypic interactions between cancer cells and blood components including endothelial cells (Figure 2 ) [3, 10] .
After entering the bloodstream directly or via lymphatics, cancer cells are transported to distant organs, where they are arrested within the microvasculature (Figure 2a ) [117, 118] . Platelet-cancer cell association and the formation of a tumor embolus during the intravascular phase is thought to be a key step during metastatic dissemination and colonization ( Figure 2b ) [14, [102] [103] [104] 119] . Cancer patients with advanced, metastatic disease have increased serum levels of markers of platelet activation and a higher percentage of activated platelets, probably indicating platelet activation during metastatic spread [104, 120] . Whether cancer cell-platelet interactions are directly initiated after intravasation or after microvascular arrest of cancer cells remains unclear.
In experimental metastasis models, formation of tumor emboli within the pulmonary microvasculature is observed rapidly after the injection of cancer cells (Figure 2b ) [105, 108] . Nevertheless, the proof for significant tumor cell emboli formation in cancer patients is hampered by pre-analytical treatment of blood samples with a considerable chance of introducing artifacts. Since the isolation methods for circulating cancer cells are becoming more standardized [121, 122] , the isolation of circulating tumor emboli may become feasible. Primary activation of platelets by cancer cells in vivo is not yet completely understood, but abundant evidence indicates the involvement of tissue factor induced formation of thrombin and signaling through protease activated receptors (PAR) [123, 124] . In mice with platelets lacking PAR4, activation of platelets was strongly reduced and metastasis diminished [107] . Besides minor roles for GPIIb/IIIa and GPIb/IX in aggregation of platelets on cancer cells [105, [125] [126] [127] , tumor emboli formation mainly depends on P-selectin mediated interactions [108] . Platelets and tumor emboli formation may promote metastasis by various means including protection from immune-mediated clearance of cancer cells through NK-cells [128, 129] , enhancement of microvascular arrest [127] , cancer cell invasion through secretion of proteases [130, 131] , as well as enhanced angiogenesis and growth through the release of various cytokines such as PDGF and VEGF and bioactive lipids like lysophosphatidic acid [14, 104, 132] . We recently provided evidence that platelets promote metastatic colonization by supporting the formation of an inflammatory niche within the lung microvasculature [4] . P-selectin mediated interactions between cancer cells, platelets and neutrophils led to a local inflammatory activation of endothelial cells [4] . Platelets can support inflammatory activation by the release of cytokines and chemokines [13] . It is conceivable that the formation of a tumor embolus through P-selectin leads to locally increased levels of platelet cytokines and chemokines. Platelet aggregation and tumor emboli formation may additionally occlude microvessels and thus lead to hypoxic areas, promoting a local inflammatory reaction. Moreover, platelet aggregation on cancer cells induces and is perpetuated by the coagulation cascade, finally resulting in increased levels of thrombin and fibrin deposition [119] . Thrombin itself can activate cancer cells and the local endothelium through PAR signaling [119, 124] , thereby potentially enhancing local inflammation.
The inflammatory microenvironment that is generated by tumor-embolus formation activates the adjacent endothelium and recruitment of leukocytes (Figure 2c) . Markers of endothelial cell activation and inflammation are up-regulated during the first hours after microvascular arrest of cancer cells in models of experimental liver and lung metastasis [88, 101, 133] . Endothelial cell activation markers such as soluble E-selectin and ICAM-1 detected in plasma are elevated in cancer patients with advanced disease [134] .
Reduction of endothelial cell activation in experimental models was associated with decreased metastasis [135, 136] . Activated endothelial cells further support local inflammatory activation and formation of a metastatic niche, mainly by mediating the recruitment of leukocytes. Recruitment and activation of inflammatory cells, in particular myeloid cells are associated with enhanced metastatic colonization [4, 85, 116, 137, 138] . Selectin mediated interactions facilitate the recruitment of leukocytes to the metastatic microenvironment [4, 83, 85] . L-selectin mediated interactions were demonstrated to be essential for the recruitment of neutrophils and monocytes in an experimental model of metastasis [83, 85] . Interactions of L-selectin with a yet unidentified FucT VII dependent ligand on activated endothelial cells contribute to recruitment of leukocytes [85] . Furthermore, selectin dependent interactions between cancer cells, platelets and neutrophils led to the up-regulation of endothelial CCL5 and subsequent recruitment of monocytes to the metastatic microenvironment [4] . Inhibition of CCL5 and subsequently reduced monocyte recruitment attenuated metastasis [4] .
Myeloid cells may support metastatic colonization by local immune-suppression, cancer cell survival, invasion and extravasation (Figure 2d ) [114, 139, 140] . Monocytes and descendant macrophages were recently shown to facilitate lung colonization by enhancing extravasation [116] . L-selectin dependent recruitment of monocytes can directly increase vascular permeability and transendothelial migration of cancer cells (L.B., manuscript in preparation). E-selectin has also been shown to contribute to the extravasation process [91] .
Many studies linking selectins to the metastatic process have utilized experimental metastasis models. A limitation of direct intravascular injection of cancer cells is the absence of a pre-metastatic niche. The pre-metastatic niche was first identified in mouse models of spontaneous metastasis and has subsequently been shown to be present in cancer patients [141] [142] [143] . Myeloid precursor cells are mobilized and recruited to specific locations by the primary tumor in an endocrine dependent manner [141] [142] [143] . Thereby myeloid cells can shape the local microenvironment in order to make it permissive for arriving cancer cells [141] [142] [143] . The role of selectins in the formation of the premetastatic niche, however, remains largely elusive and necessitates further studies and validation in human cancer patients.
Selectin-inhibitors as anti-metastatic therapeutics
The expression and involvement of selectins during inflammation, immune response and cancer led to the rationale that inhibitors of selectins could be used as anti-inflammatory, immune-modulating, and anti-cancer agents and several types of inhibitors were developed over the past years [7, 144] . Selectin inhibitors can be divided into glycanbased molecules, small molecules including glycomimetics, soluble forms of ligands and antibodies either targeting selectins or their ligands. The first tested inhibitor was a sialyl-Lewis x tetrasaccharide that could target all selectins. However the low affinity, high production costs and unfavorable pharmacokinetics made it not suitable for further development [7] . Glycometabolic inhibitors have been developed that indirectly reduce the production of selectin ligands by inhibition of relevant glycosyltransferases, in particular O-glycosylation of mucins and fucosyltransferases [144, 145] . Treatment of cancer cells with a disaccharide-based inhibitor that serves as a decoy for the glycan synthesis led to reduction of cancer cell-associated sLe x structures and subsequently to attenuation of metastasis [146, 147] . A recombinant soluble form of PSGL-1 was shown to inhibit the rolling of leukocytes in vivo, and prevents inflammation in different modes of inflammation [144, 148, 149] . However, clinical trials were discontinued partly due to high production costs [7] . Small molecules or glycomimetics including bimosiamose (TBC-1269), cylexin (CY1503) and efomycine M that inhibit selectins were tested in models of ischemia-reperfusion injury, psoriasis and asthma and to some extent evaluated in clinical trials [144, [150] [151] [152] . Selectin blocking antibodies that successfully passed preclinical evaluation were examined in patients with psoriasis, reperfusion injury or cerebral ischemia with no or only minimal clinical effect [151] .
Heparin is a glycosaminoglycan exclusively expressed and stored in mast cells and consists of N-and O-sulfated alternating galactosamine/glucosamine and glucoronic acid/iduronic acid moieties [153] . Heparin and fractionated low molecular weight heparins are clinically used for their anti-coagulant activity via antithrombin III and the pentasaccharide sequence for this effect is well characterized [153] . Moreover, unfractionated heparin and some clinically used low molecular heparins bind to P-and L-selectins and inhibit their function [108, 154, 155] . However, not all low molecular weight heparins show inhibitory activity on selectins, indicating that selectin binding to heparin requires a specific properties independent of anticoagulant activity [155, 156] .
Indeed, chemically modified heparins with minimal anticoagulant activity but retained its selectin inhibitory activity efficiently attenuated experimental metastasis [10, 108, [157] [158] [159] . Besides inhibition of selectins, heparins probably improve survival by influencing heparanase activity, growth factor signaling and inhibition of different cell adhesion molecules including integrins [36] . In clinical trials, heparins are associated with a better survival of patients [160] .
Selectins are mainly implicated in hematogenous metastasis during the intravascular phase of cancer cells. Based on the above described mechanism, heparin inhibition of P-and L-selectin should be applied immediately following initial cancer diagnosis until a period of time (e.g. a few weeks) after surgical removal of the primary tumor [161] .
Moreover, the demonstrated implication of selectins in the metastatic process warrants the application of selectin inhibitors to patients with a local tumor stage in order to prevent dissemination. Since selectins are crucial for homeostasis, it is unlikely that prolonged treatment will be feasible. Based on the proposed treatment window encompassing about two months, the specific inhibition of one or two selectins should be well tollerated. Interestingly, there is precedence for the prolonged inhibition of Pselectin. Therapeutic doses of heparin efficiently inhibit P-selectin and also L-selectin, therefore cancer patients treated with heparin as an anticoagulant inadvertently achieved significant P-selectin inhibition [154] . Clinical trials are currently ongoing that evaluate the use of low molecular weight heparins after surgery of localized tumors in addition to adjuvant systemic treatment (e.g. NCT00475098, NCT00967148). Finally, modified heparins with a selective effect on selectin inhibition or other inhibitors of selectins require further examination in preclinical models and testing in early clinical trials.
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